These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22525394)

  • 41. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
    Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
    J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J; Figliomeni M; Kianifard F; Meng X
    J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
    Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
    J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
    Garcia G; Magnan A; Chiron R; Contin-Bordes C; Berger P; Taillé C; Devouassoux G; de Blay F; Couderc LJ; Didier A; O'Callaghan DS; Girodet PO; Bourdeix I; Le Gros V; Humbert M
    Chest; 2013 Aug; 144(2):411-419. PubMed ID: 23579324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
    van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
    J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omalizumab: a review of its use in the treatment of allergic asthma.
    Plosker GL; Keam SJ
    BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.